Skip to main content
Premium Trial:

Request an Annual Quote

Three RNAi-Related Patent Applications Published by the USPTO: May 20, 2005

Premium

Title: Genes Required for Viability And/Or Reproduction in C. elegans and Their Use in the Development of Anti-Nematode Agents.

Number: 20050101773.

Filed: Sept. 8, 2003. PCT Filed Nov. 9, 2001.

Lead Inventor: : Chris Echeverri, Cenix Bioscience.

"The … invention relates to several C. elegans genes and gene products identified by means of RNA-mediated interference as required for the viability, growth, or reproduction of nematodes and to functional orthologues of said genes and gene products found in other nematode species, including all biologically-active derivatives thereof," the patent application's abstract states.

"The invention also comprises the use of said genes and gene products in the development of anti-nematode or other pesticidal agents and in methods for diagnosis and treatment of diseases associated with the infection or presence of nematodes."


Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference.

Number: 20050100913.

Filed: Aug. 20, 2003.

Lead Inventor: Craig Mello, University of Massachusetts Medical School.

According to the patent application's abstract, the invention comprises "genes involved in double-stranded RNA interference [used] to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity," the abstract adds.


Title: Method and Medicament for Inhibiting the Expression of a Given Gene.

Number: 20050100907.

Filed: July 2, 2003.

Lead Inventor: Roland Kreutzer, Ribopharma (Alnylam Europe).

"The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA," the patent application's abstract states.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.